Sökning: WFRF:(Kurth Andreas A) > Efficacy of delayed...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03062naa a2200325 4500 | |
001 | oai:gup.ub.gu.se/166356 | |
003 | SwePub | |
008 | 240528s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1663562 URI |
024 | 7 | a https://doi.org/10.1016/j.thromres.2012.08.3152 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Eriksson, Bengt I.,d 1946u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för ortopedi,Institute of Clinical Sciences, Department of Orthopaedics4 aut0 (Swepub:gu)xerben |
245 | 1 0 | a Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis. |
264 | 1 | b Elsevier BV,c 2012 |
520 | a INTRODUCTION: Oral thromboprophylaxis with dabigatran etexilate should be initiated as a half dose 1 to 4h after major orthopaedic surgery. However, a delay in dosing could occur for clinical or logistical reasons. A post hoc analysis was carried out to determine if patients with delayed dosing received adequate anticoagulation. PATIENTS AND METHODS: The RE-MODEL™ and RE-NOVATE® trials compared 220mg and 150mg dabigatran etexilate with 40mg enoxaparin. Pooled data for major venous thromboembolism (VTE) and VTE-related mortality (efficacy outcome) and major bleeding events (MBE), MBE/clinically relevant bleeding events, and all bleeding events (safety outcomes) were analysed. Results in patients with dosing delayed more than 4h postsurgery were compared with those of patients without a delay. RESULTS: Onset of treatment was delayed in 724 (13.3%) of 5425 patients. Efficacy of 220mg dabigatran etexilate was similar in patients without delayed dosing, patients with a delay and patients with a delay until the day after surgery. Rates of efficacy outcome were higher in patients on 150mg dabigatran etexilate, but more than 80% of these patients were undertreated based on age or renal clearance status. Some differences in bleeding events were seen among patient groups by treatment arm. CONCLUSION: Dabigatran etexilate thromboprophylaxis should be initiated 1 to 4h postsurgery. Results from our post-hoc analysis indicate that no loss of efficacy appears to occur if initiation of dabigatran etexilate 220mg needs to be delayed. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Ortopedi0 (SwePub)302112 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Orthopaedics0 (SwePub)302112 hsv//eng |
700 | 1 | a Dahl, Ola E4 aut |
700 | 1 | a Rosencher, Nadia4 aut |
700 | 1 | a Clemens, Andreas4 aut |
700 | 1 | a Hantel, Stefan4 aut |
700 | 1 | a Kurth, Andreas A4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för ortopedi4 org |
773 | 0 | t Thrombosis researchd : Elsevier BVg 130:6, s. 871-876q 130:6<871-876x 1879-2472x 0049-3848 |
856 | 4 8 | u https://gup.ub.gu.se/publication/166356 |
856 | 4 8 | u https://doi.org/10.1016/j.thromres.2012.08.315 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.